Introduction
Acute vestibular disorders induce severe vertigo usually associated with nausea and vomiting. Relief of these symptoms is the first task for the clinician. In many countries including the United Kingdom, prochlorperazine is perhaps the drug most commonly prescribed in the acute scenario [Patka et al., 2011] and the British National Formulary lists its indications as 'severe nausea, vomiting, vertigo, labyrinthine disorders' [Joint Formulary Committee, 2012] . Prochlorperazine suppresses vomiting by modulating messages from the vestibular system to the vomiting centres at the chemoreceptor trigger zone [Yang and Neff, 1974] yet any antivertiginous effect is unproven.
The hypothesis of the study was that oral prochlorperazine modulates vestibular-motion (ocular reflex and perceptual) signals. It is important to try to establish if the beneficial effects of the drug are due to action on the vestibular system per se, i.e. truly antivertiginous. If prochlorperazine has no effect on vestibular parameters one would have to conclude that the mechanism of action of the drug is only anti-emetic. Significant suppression of vestibular responses by prochlorperazine (our primary outcome) would also impact on the reliability of clinical testing in acute vestibular patients taking the drug. As many vertiginous patients included in clinical research projects are under the effects of this drug, the findings in our study may clarify if some of the vestibulo-ocular and vestibuloperceptual abnormalities detected acutely in patients may be due to the effects of the drug rather than the vestibular lesion itself. In particular, vestibuloperceptual time constants are particularly shortened in acute vestibular neuritis patients and it was suggested that this represented a cortical 'shutdown' with a net antivertiginous effect . However, the possibility that this perceptual effect was drug-induced was not directly investigated. We now address these questions as a double-blind, randomised, crossover, placebo-controlled, non-clinical drug trial on healthy subjects.
Methods
Twelve healthy naïve, right-handed subjects (aged 19-34 years, mean 22.7 years, 6 females), verified by clinical history, participated and gave signed consent. The study was approved by the local ethics committee. The number of subjects included was based on previous experiments using this vestibular methods in normal subjects, as in the current study [Kyriakareli et al., 2013] .
Prochlorperazine and Placebo
The local hospital pharmacy supplied prochlorperazine as the brand Stemetil as a single 5-mg unmarked film-coated tablet in an unremarkable bottle (Stemetil 5-mg tablets are bioequivalent to prochlorperazine 5-mg tablets; MHRA guidelines, PL17907/0072). The placebo (indistinct lactose) was issued identically. A computer-generated randomisation list was unknown to the authors. The 5-mg dose was chosen as it is the British National Formulary [Joint Formulary Committee, 2012] starting oral recommended dose (3 mg for the buccal preparation).
Maximum potency of a 5-mg Stemetil tablet (Bristol Laboratories Ltd., UK) is achieved after 3.1 h (MHRA, PL17907/0072). Testing was performed 3.0 h after taking the tablet, at the same time of day for each subject and all were asked to avoid caffeine. Testing took approximately 40 min and was conducted in two sessions separated by 1 week (i.e., crossover design).
Experimental Protocol
Subjects sat in a vibration-free Bárány chair (Contravez Inc.) with the head restrained by a chin rest and in complete darkness. White noise was amplified through two speakers fixed to the chair behind the head to mask any surroundings sound clues that may indicate rotation.
Given that the result of the study could be related to drug-induced changes to alertness [Nigam et al., 1985] , we performed a simple reaction time test immediately before rotational testing: pressing a button as fast as possible with the thumb of the dominant hand upon hearing a loud beep. Mean reaction time was calculated from 5 trials.
Vestibular Tests
Two tests were performed: a vestibular threshold motion detection task and a suprathreshold task in which vestibulo-ocular and perceptual time constants were measured. The order of these tests was randomised. A detailed explanation of the measurements and analysis is provided elsewhere [Cutfield et al., 2011; Okada et al., 1999] , below the methods are summarised in brief:
Vestibular Threshold Test
The chair rotated about the yaw plane (i.e., horizontally), increasing in velocity in steps of 0.5°/s 2 every 3 s. Subjects were rotated in total 10 times, 5 times to the left and 5 times to the right in random order. A 1-min rest was given between each rotation.
Subjects held a two-button box controller with both hands, pressing the left button to indicate a perceived leftward rotation and the right button when they perceived a rightward rotation. Each subject was given an identical instruction to press the right/ left button as soon as they felt motion, and to not press any button if they had any doubt about motion or direction. The time to button press indicates the vestibuloperceptual threshold ( fig. 1 a) , which can be expressed as either time (s) or chair velocity (°/s).
Eye movements were simultaneously captured through electro-oculography (EOG) sampled at 250 Hz. EOG signals were passed through a low-pass filter (cut-off 30 Hz) prior to analysis. The nystagmic or vestibulo-ocular threshold, i.e., onset time of nystagmus, was obtained from the raw eye movement trace and a differentiated and de-saccaded eye movement trace [(see Cousins et al., 2013, and Okada et al., 1999) , for further technical details].
An average perceptual and eye movement onset time was obtained.
Suprathreshold Vestibular Task
The chair was rapidly accelerated (1 s) in the yaw plane to a constant velocity of 90°/s using a rotational step stimulus [Okada et al., 1999] . The velocity was constant until the nystagmus had stopped and never less than 60 s. A total of four rotations, two in each direction, and four stopping responses were obtained. The direction order was randomised.
Subjects signalled their perceived or subjective angular velocity by turning a tachometer wheel with their right hand at the onset of perceived rotation in either direction (onset and stopping responses). Instructions were given to subjects to turn the wheel as fast as comfortably possible initially on chair acceleration/deceleration for the first couple of seconds. From then on they should slow down the wheel turning congruently with their perceived angular velocity until they no longer felt rotating, at which point they should stop turning the wheel. All subjects turned the wheel in the direction of actual motion. An output voltage proportional to the angular velocity of the wheel was digitally sampled at 250 Hz. An average waveform was normalised for size variations between subjects; accordingly amplitude units are arbitrary and hence not considered further herewith.
Eye movements were simultaneously captured with EOG sampled at 250 Hz and passed through a low-pass filter (cut-off 30 Hz) prior to analysis. The EOG signals were displayed raw and also differentiated, de-saccaded and visible artefacts removed (i.e., blinks). An averaged, calibrated and normalised in amplitude slow phase eye movement trace was obtained for each subject.
Analysis of tachometer-wheel (vestibuloperceptual) and slow phase eye movement (vestibulo-ocular) suprathreshold responses ( fig. 1 b) 93 of the perceptual responses, and the (normalised) area under the curve was obtained. Also, an exponential was fitted to the perceptual and slow phase eye velocity movements attaining the time constant of decay of the vestibulo-ocular and vestibuloperceptual responses; in this way the ocular and perceptual velocity storage mechanisms are assessed [Bertolini et al., 2011; Shaikh et al., 2013] . The time constant was derived from the best fit exponential line by visual overlap of a computer-generated curve and response curve and high correlation coefficient (r, fig. 1 c) . This measure is amplitude-independent. Gain of the slow phase eye movement response (vestibulo-ocular reflex, VOR) was calculated, defined as peak eye velocity per peak stimulus velocity (90°/s).
Statistical Analysis
Data analysis of responses was performed by 2 blinded examiners. An unblinded statistician compared the responses between examiners and performed all statistics (J.G.). Mixed ANOVAs with factors: drug, order, examiner were employed as well as paired t tests for specific investigations (reaction time test, examiner effect, direction of rotation). Significance level was set as double-tailed (p < 0.05).
Results
The 2 examiners' analyses of rotational responses were similar and no interaction between examiner and drug effect was found. The mean from the 2 blinded examiners' analyses was therefore used.
Blinded participants were unable to distinguish between the two tablets and none experienced an adverse response. Oculomotor recordings from 1 subject (subject 7) were lost.
Mean reaction time was very similar and not significantly different between prochlorperazine (0.25 s) and placebo (0.23 s).
Vestibulo-Ocular and Vestibuloperceptual Threshold Tasks
Upon perceiving angular movement, all subjects pressed either the right or left button as instructed. On three occasions, different subjects pressed the incorrect button for direction and this response was excluded (once on placebo). Nystagmic thresholds were attained quicker than perceptual thresholds, as observed in previous research . There was no significant difference between leftward and rightward rotations.
As illustrated in figure 2 , nystagmic threshold for prochlorperazine was 6.3 s (SEM ±0.24) and placebo 6.7 s (SEM ±0.2) from the onset of rotation, corresponding to a mean chair rotational velocity of 4.9 and 5.7°/s, respectively. Perceptual threshold for prochlorperazine was 10.0 s (SEM ±1.17) and placebo 10.23 s (SEM ±1.18), which correspond to a mean chair rotational velocity of 11.0 and 11.8°/s, respectively. ANOVA showed no drug or order effect for any measure of nystagmic or perceptual threshold during the vestibular motion detection task.
Vestibulo-Ocular and Vestibuloperceptual Suprathreshold Task
During rotation, all subjects turned the tachometer wheel in the direction of movement, always stopping wheel rotation before 60 s. Upon stopping the chair's rotation, all subjects turned the wheel toward the opposite direction reflecting a perceived change in movement direction. There was no significant difference between leftward and rightward rotations.
As shown in figure 3 , nystagmic duration for prochlorperazine was 39.5 s (SEM ±1.28) and placebo 42.5 s (SEM ±1.19). Nystagmic time constant for prochlorperazine was 13.85 s (SEM ±0.76) and placebo 14.65 s (SEM ±0.74). Nystagmic area under the curve for prochlorperazine was 51.9° (SEM ±15.0) and placebo 51.6° (SEM ±9.99). VOR gain for prochlorperazine was 0.45 and placebo 0.52. Perceptual duration of rotation for prochlorperazine was 26.5 s (SEM ±2.81) and placebo 31.43 s (SEM ±3.27). Perceptual time constant for prochlorperazine was 15.02 s (SEM ±1.64) and placebo 16.62 s (SEM ±1.92). Perceptual area under the curve for prochlorperazine was 70.94 arbitrary units (AU, SEM ±10.57) and placebo 82.06 AU (SEM ±11.36).
ANOVA showed no drug or order effect on any measure of nystagmus or motion perception, i.e., there was no difference between prochlorperazine and placebo.
Discussion
We found no significant effects of prochlorperazine upon any measure of ocular or perceptual function.
Vestibular Motion Detection -Threshold Task
The vestibular motion detection technique used has previously shown elevated bilateral vestibulo-ocular and vestibuloperceptual thresholds in acute unilateral vestibular neuritis Cutfield et al., 2011] . One pending question was whether the antivertiginous drugs some of these patients received (usually prochlorperazine in the UK) played any role in this bidirectional threshold elevation. This would make sense as ideally a vestibular suppressant drug should elevate vestibular thresholds, in particular perceptual. The present results attest against this possibility and hence, the bilateral threshold elevation observed in acute vestibular neuritis is likely the result of the reduced signal-to-noise ratio following the vestibular loss as postulated by Cousins et al. [2013] .
Vestibular Velocity Storage MechanismSuprathreshold Task
The normal prolongation of vestibular-ocular and perceptual time constants to values of 13-16 s (i.e. double those of the vestibular nerve time constant) [Ramat and Bertolini, 2009 ] is due to a central integrator known as 'velocity storage' [Raphan et al., 1979] . Professional dancers, figure skaters and jet fighter pilots [Cohen et al., 2003] show reduced vestibular time constants due to a process of vestibular habituation thought to involve velocity storage processing. For this reason, we expected that any antivertiginous or vestibular suppressant effects (as these drugs are often referred to) of prochlorperazine would involve the velocity storage mechanism, presumably shortening vestibular nystagmic and/or perceptual time constants. However, we found no effect of prochlorperazine on the time constants of decay of the vestibulo-ocular or vestibuloperceptual postrotational responses or the gain of the VOR. Contrastingly, baclofen, a GABA-B agonist, reduces the vestibular time constant [Dai et al., 2006] , whereas promethazine (a drug with antihistaminic H1/anticholinergic properties) has no effect [Cohen et al., 2003] .
Prochlorperazine reduces vomiting by inhibiting dopamine (D2) receptors [Yang and Neff, 1974 ]. As we found no effect of prochlorperazine on vestibular function tests, and given that the primary mechanism of action of prochlorperazine is as a dopamine antagonist, our results suggest that dopaminergic involvement in the vestibular system is small. Indeed, only a small number of dopaminergic neurones can be found in the medial vestibular nucleus of rats [Cransac et al., 1996] .
Study Limitations
Although the current experiment was performed in a young cohort, the responses were consistent with those of older adults, age-matched to vestibular neuritis patients . In addition, we used healthy subjects as opposed to patients who might have a different response to prochlorperazine. However, our past investigations show that patients taking prochlorperazine respond within the same range to patients who are not on the drug during the same vestibular tests used here . Still, the drug effects in patients would need to be specifically studied.
Conclusions
Whilst oral prochlorperazine is an accepted therapy for vomiting and nausea, it seems to have no effect on vestibular motion detection or on the vestibular velocity storage mechanism (ocular and perceptual). Therefore it would seem to offer little relief for unwanted vestibularmediated motion feelings (vertigo) in dizzy patients. Prochlorperazine is unlikely to affect clinical assessments of vestibular function (nystagmic or perceptual) in dizzy patients, but it has to be acknowledged that our study was only conducted in normal subjects. The beneficial effects of prochlorperazine, and perhaps related drugs, may be due to anti-emetic action. Higher doses of this drug may well have an effect on vestibular function but clinical experience and pharmacological studies [Nigam et al., 1985] indicate that, at higher doses, general CNS effects, alertness and cognitive in particular, would be very difficult to disentangle from true central vestibular effects.
